Kaga, Hajime
Matsumura, Hirotoshi
Suzuki, Takehiro
Dohmae, Naoshi
Odaka, Masafumi
Komatsuda, Atsushi
Takahashi, Naoto
Wakui, Hideki
Funding for this research was provided by:
Japanese Society for the Promotion of Science (19K08694)
Article History
Received: 15 January 2022
Accepted: 30 June 2022
First Online: 14 July 2022
Declarations
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the Ethics Committees of Akita University Hospital (approval number: 1830) and RIKEN Center (approval number: Wako3 2019-17), and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.
: We agree for publication upon acceptance and we agree that all copyright ownership for the article is transferred to Clinical Proteomics. The material submitted is new, original and has not been submitted to another journal for concurrent consideration.
: Dr. Naoto Takahashi has received grants and personal fees from Novartis Pharmaceuticals, grants and personal fees from Pfizer, grants and personal fees from Otsuka Pharmaceutical, grants from Kyowa Kirin, grants from Astellas Pharma, grants from Asahi Kasei Pharma, grants from Ono Pharmaceutical, and grants from Mochida Pharmaceuticals, outside of the submitted work. The remaining authors declare that they have no competing interests.